{"filing":{"accession_number":"0001193125-26-387232","cik":"0001678660","ticker":"PRLD","company_name":"Prelude Therapeutics Inc","form":"8-K","filing_date":"2026-09-10","report_date":"2026-09-10","primary_document":"prld-20260910.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1678660/000119312526387232/prld-20260910.htm"},"events":[{"id":32520,"run_id":29882,"accession_number":"0001193125-26-387232","anchor_item_number":"7.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"Prelude announced FDA clearance to proceed with a Phase 1 clinical study for PRT13722, a KAT6A degrader for HR+ breast cancer treatment, with patient enrollment anticipated in Q4 2026. This is a material regulatory milestone and clinical development advancement for a precision oncology company's lead program, affecting investor assessment of pipeline progress and value creation, but does not fit the specific categories of earnings release, M\u0026A, impairment, or other defined event types. The disclosure centers on a significant operational and regulatory milestone in drug development.","company_name":"Prelude Therapeutics Inc","ticker":"PRLD","filing_date":"2026-09-10","form":"8-K","submitted_at":null,"items":[{"id":35711,"accession_number":"0001193125-26-387232","item_number":"7.01","item_title":"Regulation FD Disclosure","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Prelude announced FDA clearance to proceed with a Phase 1 clinical study for PRT13722, a KAT6A degrader for HR+ breast cancer treatment, with patient enrollment anticipated in Q4 2026. This is a material regulatory milestone and clinical development advancement for a precision oncology company's lead program, affecting investor assessment of pipeline progress and value creation, but does not fit the specific categories of earnings release, M\u0026A, impairment, or other defined event types. The disclosure centers on a significant operational and regulatory milestone in drug development.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-10T11:31:41.441624+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":35711,"accession_number":"0001193125-26-387232","item_number":"7.01","item_title":"Regulation FD Disclosure","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Prelude announced FDA clearance to proceed with a Phase 1 clinical study for PRT13722, a KAT6A degrader for HR+ breast cancer treatment, with patient enrollment anticipated in Q4 2026. This is a material regulatory milestone and clinical development advancement for a precision oncology company's lead program, affecting investor assessment of pipeline progress and value creation, but does not fit the specific categories of earnings release, M\u0026A, impairment, or other defined event types. The disclosure centers on a significant operational and regulatory milestone in drug development.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-10T11:31:41.441624+00:00","company_name":"Prelude Therapeutics Inc","ticker":"PRLD","filing_date":"2026-09-10"}]}